Liquidia (NASDAQ:LQDA) Given New $32.00 Price Target at HC Wainwright

Liquidia (NASDAQ:LQDA) had its price objective upped by HC Wainwright from $16.00 to $32.00 in a research note released on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms have also recently weighed in on LQDA. Wedbush reaffirmed an underperform rating and set a $3.00 price objective on shares of Liquidia in a research report on Thursday, December 21st. Needham & Company LLC reaffirmed a buy rating and set a $28.00 price objective on shares of Liquidia in a research report on Wednesday, February 21st. LADENBURG THALM/SH SH increased their target price on shares of Liquidia from $15.00 to $30.00 and gave the stock a buy rating in a report on Thursday, December 21st. Finally, Bank of America increased their target price on shares of Liquidia from $13.00 to $15.00 and gave the stock a buy rating in a report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $21.00.

Liquidia Price Performance

Shares of NASDAQ:LQDA traded down $0.34 during mid-day trading on Thursday, reaching $15.56. 921,783 shares of the company were exchanged, compared to its average volume of 984,532. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -13.05 and a beta of 0.14. The firm’s 50-day simple moving average is $13.71 and its 200 day simple moving average is $9.61. Liquidia has a 1 year low of $5.71 and a 1 year high of $16.51.

Institutional Investors Weigh In On Liquidia

Hedge funds and other institutional investors have recently modified their holdings of the company. Fortitude Family Office LLC acquired a new stake in shares of Liquidia in the 4th quarter valued at $26,000. Tower Research Capital LLC TRC raised its stake in Liquidia by 101.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,004 shares of the company’s stock worth $55,000 after acquiring an additional 3,524 shares in the last quarter. UBS Group AG raised its stake in Liquidia by 134.0% during the 2nd quarter. UBS Group AG now owns 7,948 shares of the company’s stock worth $35,000 after acquiring an additional 4,552 shares in the last quarter. Legal & General Group Plc acquired a new stake in Liquidia during the 2nd quarter worth $38,000. Finally, BNP Paribas Arbitrage SNC raised its stake in Liquidia by 20.5% during the 1st quarter. BNP Paribas Arbitrage SNC now owns 9,993 shares of the company’s stock worth $69,000 after acquiring an additional 1,702 shares in the last quarter. 45.03% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.